Dulaglutide

Overview

Dulaglutide, marketed as Trulicity, is an FDA-approved prescription medication for the treatment of type 2 diabetes. It belongs to the class of GLP-1 receptor agonists and is designed for convenient once-weekly subcutaneous injection. Dulaglutide is a larger, engineered molecule in which a GLP-1 analog is fused to a fragment of an antibody, a design that extends its duration of action and allows the weekly dosing schedule.

It is used alongside diet and exercise to improve blood sugar control in adults with type 2 diabetes, and it may be used alone or in combination with other diabetes medications depending on the clinical situation. The once-weekly format is often valued for its convenience compared with daily or twice-daily injectable options.

As an approved and widely studied medicine, dulaglutide has a well-characterized profile of benefits and risks. It is intended specifically for type 2 diabetes management under medical supervision and, like other approved GLP-1 agonists, should be clearly distinguished from unregulated peptides. Its substantial clinical trial program provides a robust evidence base, which supports informed discussions between patients and their healthcare providers about whether it is an appropriate option.

How it works

Dulaglutide works by activating GLP-1 receptors, mimicking the natural incretin hormone glucagon-like peptide-1. Through this action, it stimulates the pancreas to release insulin in a glucose-dependent manner, meaning insulin secretion is promoted primarily when blood sugar is elevated. This glucose-dependence helps reduce the likelihood of hypoglycemia relative to some other diabetes treatments.

In addition to enhancing insulin release, dulaglutide suppresses excess glucagon secretion when blood sugar is high and slows gastric emptying, which moderates the rise in glucose after meals and can promote a sense of fullness. These combined effects improve overall glycemic control and may contribute to modest weight reduction in many patients, a feature common to the GLP-1 receptor agonist class.

The molecule's structure is central to its weekly dosing. By fusing a GLP-1 analog to a portion of an immunoglobulin fragment, dulaglutide becomes a large protein that is cleared from the body slowly and resists rapid enzymatic breakdown. This engineered design maintains steady GLP-1 receptor activation over the course of a week, allowing a single weekly injection to provide continuous therapeutic effect.

Clinical evidence

Dulaglutide has been studied in an extensive clinical trial program, including the AWARD series of trials, which evaluated its effects on blood glucose control across a range of patient populations and treatment combinations. These studies demonstrated meaningful reductions in HbA1c, supporting its approval and use as an effective option for managing type 2 diabetes. Modest weight reduction was also commonly observed.

A particularly significant study is the REWIND trial, a large cardiovascular outcomes trial. REWIND assessed whether dulaglutide could reduce major adverse cardiovascular events in people with type 2 diabetes, including many participants who did not have established cardiovascular disease at baseline. The trial showed a cardiovascular benefit, indicating that dulaglutide reduced the risk of these events in the studied population.

This demonstrated cardiovascular benefit is an important and positive aspect of dulaglutide's profile, distinguishing it from agents that have shown only neutral cardiovascular results. It means that for appropriate patients, dulaglutide may offer advantages beyond glucose lowering. As always, these findings are interpreted in the context of the specific populations studied, and treatment decisions weigh the full picture of benefits, risks, and individual patient circumstances.

Dosing & side effects

Dulaglutide is given as a once-weekly subcutaneous injection using a prefilled device, and it does not require dose timing around meals. This article does not provide specific doses or titration schedules; the appropriate regimen is determined by a prescribing clinician based on the individual patient, treatment goals, and response. Patients are typically instructed on proper use of the injection device and on selecting injection sites.

The most common side effects are gastrointestinal, especially nausea, which tends to be most prominent when treatment begins and often diminishes over time. Diarrhea, vomiting, abdominal discomfort, and reduced appetite can also occur. When combined with certain other glucose-lowering drugs, such as sulfonylureas or insulin, the risk of hypoglycemia may rise, which is one reason ongoing medical supervision matters.

Less common but more serious concerns associated with the GLP-1 class include pancreatitis and, based on animal studies, a labeled warning regarding thyroid C-cell tumors, making it contraindicated in people with certain thyroid cancer histories. Patients should review the official prescribing information with their healthcare provider and report severe abdominal pain or other concerning symptoms promptly. Decisions about dulaglutide should be made with a qualified clinician.

Legal status

Dulaglutide is a fully FDA-approved prescription medication in the United States, sold under the brand name Trulicity. It is approved for the treatment of type 2 diabetes and, based on its cardiovascular outcomes data, has a recognized role in reducing cardiovascular risk in appropriate patients. It is available only by prescription and is dispensed through legitimate pharmacy channels.

As a regulated medicine, dulaglutide is subject to rigorous manufacturing standards, quality control, labeling requirements, and ongoing safety monitoring. This oversight ensures the identity, purity, and consistency of the product, distinguishing it clearly from unapproved or research-grade peptides that lack such safeguards. It is also approved in numerous other countries for the management of type 2 diabetes.

Consumers should be cautious of any source offering dulaglutide outside of the prescription and pharmacy system, as bypassing these channels removes essential protections and may carry legal and health risks. This article is educational and does not constitute medical advice. Anyone considering dulaglutide for diabetes management should consult a qualified healthcare professional who can determine whether it is suitable and supervise its safe and effective use.

Frequently asked questions

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

1. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019. Peer-reviewed study
2. Jendle J, Grunberger G, Blevins T, et al. Efficacy and safety of dulaglutide in type 2 diabetes: review of the AWARD phase 3 program. Diabetes Metab Res Rev. 2016. Peer-reviewed study
3. Nicholls SJ, Pavo I, Bhatt DL, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. 2025. Peer-reviewed study
4. Nicholls SJ, Bhatt DL, Buse JB, et al. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. Am Heart J. 2024. Peer-reviewed study
5. Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018. Peer-reviewed study
6. Inagaki N, Takeuchi M, Oura T, et al. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022. Peer-reviewed study